Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q1 2023 call → NOWe need to determine if the company receives advance payments or binding commitments from its counterparties before delivering, and if management treats this as growing and financing future growth. Scan the transcript for mentions of deposits, prepayments, advance payments, signed but not commenced leases, etc. Key points: - Signed but not commenced leases: $56 million of ABR that will commence over next several quarters. This is a binding commitment from tenants to pay rent in the future, but it's not necessarily "advance" payment; it's a lease that hasn't started. The tenant will pay rent when the lease commences, not before. So it's not advance funding. - The company has a pipeline of leases under LOI, but those are not binding. - No mention of deposits, prepayments, or tenants paying before receiving space. - The company's revenue is from rent, which is typically paid in advance (monthly rent), but that's standard and not notable. - The question asks about "money or binding financial commitment arriving at the company ahead of the work it will pay for" - i.e., counterparties paying before delivery. In real estate, rent is paid for the use of space, typically monthly in advance, but that's normal. The signed but not commenced leases are commitments to pay in the future, but the tenant hasn't paid yet. So it's not advance funding. Management does not describe any advance payments or deposits. They talk about leasing momentum, signed leases, but those are future obligations, not current cash. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.